Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 222 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Geriatric Population Clear all
Completed Phase 3 Interventional

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

NCT05686070
View directory record Official record
Conditions
Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
Interventions
Asundexian (BAY2433334), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
12,327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
108
States / cities
Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 23, 2026, 4:03 AM EDT
Active, not recruiting Phase 4 Interventional

Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

NCT06173661
View directory record Official record
Conditions
Migraine, Menstrual Migraine, Menstrually Related Migraine
Interventions
Fremanezumab, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Geriatric Anorexia Study 2.0

NCT05211973
View directory record Official record
Conditions
Healthy, Frailty
Interventions
Wrist Actigraphy Device, Smart Body Weight Scale, Chair Scale, Handheld Body Fat Percentage Device, Bioelectric Impedance Analysis Scale
Device
Lead sponsor
Boston University
Other
Eligibility
65 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting

NCT02520388
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
Drug
Lead sponsor
Ironshore Pharmaceuticals and Development, Inc
Other
Eligibility
6 Years to 12 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
21
States / cities
Newport Beach, California • Bradenton, Florida • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2021 · Synced Jul 23, 2026, 4:03 AM EDT
Recruiting Phase 3 Interventional

Head and Neck Cancer Study Project in the Geriatric Population

NCT06998069
View directory record Official record
Conditions
Head and Neck Neoplasms
Interventions
Arm I Carboplatin, Paclitaxel, Pembrolizumab, Arm II Carboplatin, Paclitaxel, Cetuximab, Arm III Pembrolizumab
Drug
Lead sponsor
Brown University
Other
Eligibility
65 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Jul 23, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

NCT00953706
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
34
States / cities
Birmingham, Alabama • Anchorage, Alaska • Oakland, California + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2015 · Synced Jul 23, 2026, 4:03 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Melatonin Use in the Intensive Care Elderly Population

NCT03013790
View directory record Official record
Conditions
Delirium, Melatonin
Interventions
Melatonin
Drug
Lead sponsor
MICE Trial Group
Other
Eligibility
65 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Pueblo, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 4 Interventional

Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder

NCT00171184
View directory record Official record
Conditions
Overactive Bladder
Interventions
Darifenacin, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
65 Years and older
Enrollment
400 participants
Timeline
2005 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Jul 23, 2026, 4:03 AM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

NCT06641076
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Sonelokimab, Placebo
Drug
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
960 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
28
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Pharmacokinetics of Isavuconazole in Healthy Non-Elderly and Elderly Male and Female Subjects

NCT01657890
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Healthy Volunteers, Safety and Tolerability in Elderly
Interventions
isavuconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Jul 23, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder

NCT02075047
View directory record Official record
Conditions
Bipolar Disorder
Interventions
placebo oral capsules, ziprasidone oral capsules
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
46
States / cities
Dothan, Alabama • Little Rock, Arkansas • Anaheim, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Brief App-based Mobile Health and Well-being Intervention Among Middle-aged Adults

NCT04272138
View directory record Official record
Conditions
Meditation, Control Group
Interventions
Calm Meditation, Educational Podcast Control
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
40 Years to 64 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 27, 2022 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

SPD489 in Adults Aged 18-55 Years With Moderate to Severe Binge Eating Disorder

NCT01718509
View directory record Official record
Conditions
Binge Eating Disorder
Interventions
SPD489 (Lisdexamfetamine dimesylate), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
45
States / cities
Tucson, Arizona • Beverly Hills, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

NCT04473690
View directory record Official record
Conditions
Covid19
Interventions
Low Dose of KBP-COVID-19, High Dose of KBP-COVID-19, Placebo
Biological
Lead sponsor
KBio Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
6
States / cities
West Palm Beach, Florida • Meridian, Idaho • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-CFTR Mutation

NCT02516410
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-661 plus ivacaftor combination, Ivacaftor, Placebo (matched to VX-661 plus ivacaftor combination), Placebo (matched to ivacaftor)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
22
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2018 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects

NCT01655771
View directory record Official record
Conditions
Constipation
Interventions
TD-1211 Dose 1, TD-1211 Dose 2
Drug
Lead sponsor
Glycyx Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807923
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
48
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2015 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Sleep Laboratory Study to Investigate the Safety and Efficacy of Neu-P11 in Primary Insomnia Patients

NCT01489969
View directory record Official record
Conditions
Primary Insomnia
Interventions
Neu-P11
Drug
Lead sponsor
Neurim Pharmaceuticals Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
9
States / cities
San Diego, California • Hallandale, Florida • South Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03349060
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Birmingham, Alabama • Encinitas, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.

NCT00159913
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Children
Interventions
Sildenafil citrate, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
10
States / cities
Palo Alto, California • Stanford, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 23, 2026, 4:03 AM EDT
Terminated Not applicable Interventional

Human Amniotic Membrane On Venous Leg Ulcers In an Elderly Population

NCT06544564
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Membrane Wrap™, Standard of Care
Device · Other
Lead sponsor
BioLab Holdings
Industry
Eligibility
50 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
9
States / cities
Mesa, Arizona • San Franciso, California • DeLand, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03575871
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
PF-04965842 100 mg, PF-04965842 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
28
States / cities
Anaheim, California • Los Alamitos, California • Rolling Hills Estates, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 23, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

NCT01358734
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions
Azacitidine, Lenalidomide, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
65 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
24
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Jul 23, 2026, 4:03 AM EDT